transitional cell carcinoma

Type: Keyphrase

Name: transitional cell carcinoma

First Reported Mar 20 2010 - Updated Mar 20 2010 - 1 Documents

Prognostic Factors for Urothelial Cancer Identified

FRIDAY, March 19 (HealthDay News) -- For patients with transitional cell carcinoma of the urothelial tract (TCCU) that is refractory to platinum-based therapy, prognostic factors for overall survival include liver involvement, low hemoglobin, and performance ... [Published Mar 20 2010 by Modern Medicine]

Entities: Hemoglobin, Cancer, Metastasis

First Reported Mar 10 2010 - Updated Mar 10 2010 - 1 Documents

Urethral Cancer Symptoms

Urethral Cancer The urethra is the tube that carries urine from the bladder to outside the body. In women, the urethra is about 1 inches long and is just above the vagina. In men, the urethra is about 8 inches long, and goes through the ... [Published Mar 10 2010 by MedicineNet.com]

Entities: Gland, Prostate, transitional cell carcinoma

First Reported Mar 05 2010 - Updated Mar 05 2010 - 1 Documents

Just Ask the Expert: Timothy M. Fan, DVM, DACVIM

Does piroxicam have any effect in cats with transitional cell carcinoma of the bladder?By: Timothy M. Fan, DVM, PhD, DACVIM (small animal internal medicine, oncology)VETERINARY MEDICINEDr. Fan welcomes oncology questions from veterinarians and veterinary ... [Published Mar 05 2010 by Thomson Veterinary Healthcare Communications]

Entities: Piroxicam, transitional cell carcinoma, Oncology, Pharmacokinetics

First Reported Mar 03 2010 - Updated Mar 03 2010 - 1 Documents

Thermal lasers in urology

Rieken M et al. In the treatment of benign prostate hyperplasia (BPH), holmium laser enucleation of the prostate (HoLEP) and photoselective vaporization of the prostate (PVP) have proven as reliable, safe and effective treatment alternatives. Urethral ... [Published Mar 03 2010 by MDLinx]

Entities: Prostate, transitional cell carcinoma, enucleation, hyperplasia

First Reported Feb 25 2010 - Updated Feb 25 2010 - 1 Documents

Primary transitional cell carcinoma of the prostate: a male disease with dismal prognosis despite cisplatin-based systemic chemotherapy

Angulo JC et al. Despite combined therapeutic efforts that pursued both local control and the prevention of a systemic relapse, the prognosis of advanced primary prostatic urothelial carcinoma remains dismal. Early diagnosis appears difficult because ... [Published Feb 25 2010 by MDLinx]

Entities: transitional cell carcinoma, systemic chemotherapy, Prostate

First Reported Feb 21 2010 - Updated Feb 21 2010 - 1 Documents

Suggestions for Regulatory Agency Approval of Second-Line Systemic Therapy for Metastatic Transitional Cell Carcinoma [Correspondence]

3 Indiana University Cancer Center, Indianapolis, IN 4 Compehensive Cancer Centers of Nevada, Las Vegas, NV 5 Southwest Oncology Group, Rochester Hills, MI 6 San Camillo Forlanini Hospital, Rome, Italy CiteULike Complore Connotea Del.icio.us ... [Published Feb 21 2010 by Journal of Clinical Oncology]

Entities: transitional cell carcinoma, systemic therapy, Metastatic

Quotes

"We identified and both internally and externally validated three adverse risk factors (performance status, hemoglobin level, and liver metastasis) that predict for overall survival and developed a scoring system that classifies patients with platinum-refractory disease on second-line chemotherapy into four risk groups with different outcome. Similar to the first-line setting, the presence of visceral metastases and poor performance status predict a worse prognosis. These factors, together with low hemoglobin, can be used for prognostication and future patient stratification in clinical trials" the authors write

Prognostic Factors for Urothelial Cancer Identified [Modern Medicine - Mar 20 2010]

...Jean-Pierre Garnier, chief executive officer of Pierre Fabre SA, stated, "The favourable opinion of the CHMP for Javlor confirms the therapeutic interest of our anticancer product, strengthened by the clinical data of our file. Again, it rewards the quality of work done by our colleagues dedicated to R&D. Javlor will introduce innovative therapy to physicians and patients in an area considered as an unmet medical need." This approval is a significant milestone for Laboratoires Pierre Fabre as Javlor represents one of the leading products of their pipeline and these positive...

Laboratoires Pierre's bladder cancer drug Javlor gets EMEA positive opinion [PharmaBiz - Jun 30 2009]